Cerebral Atherosclerosis
Cerebral atherosclerosis refers to the hardening and narrowing of arteries supplying the brain due to the buildup of atherosclerotic plaques. This condition is a specific manifestation of systemic atherosclerosis, where fatty deposits, cholesterol, cellular waste products, calcium, and fibrin accumulate on the inner lining of arterial walls, forming plaques. Over time, these plaques can grow, stiffen, and obstruct blood flow, or they can rupture, leading to the formation of blood clots that further impede circulation.
Biological Basis
Section titled “Biological Basis”The development of cerebral atherosclerosis is a complex process involving endothelial dysfunction, inflammation, lipid accumulation, and the proliferation of smooth muscle cells within the arterial wall. Genetic factors play a significant role in an individual’s susceptibility to atherosclerosis across various vascular beds, including the carotid arteries which supply blood to the brain.[1]Genome-wide association studies (GWAS) have identified numerous genetic loci associated with subclinical atherosclerosis traits, such as carotid intima-media thickness (cIMT) and carotid plaque, which serve as indicators of arterial health and atherosclerotic burden.[2]For instance, specific genetic variants have been linked to carotid artery stenosis, a measure of advanced atherosclerosis.[3] Studies also explore the genetic architecture of cerebral blood flow. [4] The ENCODE Project, an integrated encyclopedia of DNA elements, contributes to understanding the regulatory landscape of genes involved in such diseases. [5]
Clinical Relevance
Section titled “Clinical Relevance”Cerebral atherosclerosis is a primary risk factor for ischemic stroke, a major cause of disability and mortality globally.[6]The narrowing of cerebral arteries can reduce blood supply to brain tissue (ischemia), while plaque rupture can lead to emboli that block smaller vessels. Beyond acute stroke, chronic cerebral ischemia due to atherosclerosis can contribute to vascular cognitive impairment and dementia. Early detection and characterization of subclinical atherosclerosis, particularly in the carotid arteries, are critical for identifying individuals at high risk for future cardiovascular events and implementing preventive strategies.[2]
Social Importance
Section titled “Social Importance”The high prevalence and severe consequences of cerebral atherosclerosis, particularly its strong association with stroke and cognitive decline, underscore its substantial social importance. It imposes a considerable burden on public health systems, healthcare expenditures, and societal productivity. Research into the genetic underpinnings of cerebral atherosclerosis aims to improve risk stratification, enable personalized prevention strategies, and identify novel therapeutic targets. Large-scale genetic studies, including multi-ancestry GWAS, are actively working to uncover the genetic architecture of stroke and its related vascular traits[7] ultimately contributing to better public health outcomes.
Limitations
Section titled “Limitations”Methodological and Phenotypic Heterogeneity
Section titled “Methodological and Phenotypic Heterogeneity”Variations in ultrasound protocols and plaque definitions across different studies introduce heterogeneity in phenotypic measurements, which can potentially compromise the detection of subtle genetic associations . Understanding the specific roles of these variants and their associated genes provides insight into the molecular mechanisms underlying cerebral atherosclerosis.
Several variants are found within or near genes involved in RNA regulation and pseudogene activity, which can subtly modulate cellular processes critical for vascular health. For instance, rs550610210 is associated with LINC01853 and MTCO1P44, while rs116862240 is near MIR4303 and RNU4-41P. LINC01853 and LINC02929 (associated with rs143383679 ) are long intergenic non-coding RNAs (lincRNAs), which are known to regulate gene expression, influencing processes like inflammation, cell proliferation, and lipid metabolism that are central to atherosclerosis development. Similarly,MIR4303is a microRNA, a class of small non-coding RNAs that post-transcriptionally regulate gene expression, with many miRNAs implicated in endothelial function, vascular smooth muscle cell behavior, and inflammatory responses in atherosclerotic lesions. Pseudogenes likeMTCO1P44, RNU4-41P, RPSAP72 (linked to rs2603462 ), CHORDC1P5 (linked to rs61776730 ), and CASP3P1 (also linked to rs61776730 ) can also exert regulatory functions by acting as miRNA sponges or competing with their parent genes, thereby subtly influencing gene networks relevant to cardiovascular disease.[7]
Other variants highlight genes involved in fundamental cellular signaling, lipid metabolism, and immune responses. The variant rs191973044 is associated with UBASH3B, a gene involved in ubiquitination pathways that regulate protein degradation and cellular signaling, including immune responses and inflammation, which are key drivers of atherosclerotic plaque progression. The region around rs143750482 encompasses LY6H and GPIHBP1. GPIHBP1is particularly significant as it is essential for the transport of lipoprotein lipase (LPL) to the capillary endothelium, where it hydrolyzes triglycerides in chylomicrons and VLDL. Dysfunctions inGPIHBP1can lead to severe hypertriglyceridemia, a major risk factor for atherosclerosis.LY6H, a lymphocyte antigen, may play a role in immune cell interactions within the vascular wall. Additionally, rs7902929 is located near SORCS3, a gene belonging to a family of receptors involved in protein sorting and signaling, which can influence neuronal function and potentially vascular integrity. [8]
Finally, variants like rs61944465 near WASF3 and GPR12, rs2603462 near TENT5A, and rs76828179 near FGD4 point to roles in cytoskeletal dynamics and RNA processing. WASF3 and FGD4are involved in regulating the actin cytoskeleton, which is critical for cell migration, adhesion, and vessel wall remodeling – processes central to both the initiation and progression of atherosclerosis. Endothelial cell migration and the invasion of immune cells into the arterial wall are dependent on these cytoskeletal rearrangements.GPR12 encodes a G protein-coupled receptor, a class of receptors that mediate diverse cellular responses to extracellular signals, impacting vascular tone and inflammation. TENT5A (also known as ZCCHC6) is involved in RNA uridylation, a post-transcriptional modification that can influence RNA stability and function, thereby indirectly affecting gene expression pathways relevant to vascular health and disease.[1]Collectively, these genetic variations highlight the complex interplay of regulatory RNAs, protein degradation pathways, lipid metabolism, immune responses, and cellular architecture in the development of cerebral atherosclerosis.
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Core Definitions of Cerebral and Carotid Atherosclerosis
Section titled “Core Definitions of Cerebral and Carotid Atherosclerosis”Atherosclerosis is a chronic inflammatory disease characterized by the thickening and hardening of arterial walls due to plaque accumulation. Within the context of cerebral circulation, this primarily manifests as carotid atherosclerosis, a significant indicator of systemic vascular health and a risk factor for cerebrovascular events.[1]The term “subclinical atherosclerosis” (SCA) encompasses early, asymptomatic forms of the disease detectable through imaging in various arterial territories, including the carotid arteries, coronary arteries, aorta, and peripheral arteries.[1]
Key manifestations in the cerebral vasculature include carotid intima-media thickness (cIMT), defined as the mean of the maximum measurements of the common carotid artery, typically averaged from both the left and right arteries at either the far or near wall. [9] Another crucial indicator is carotid plaque, which represents atherosclerotic thickening of the carotid artery wall. [9]These measures are pivotal for understanding the presence and extent of subclinical disease.
Diagnostic and Classification Systems for Atherosclerotic Disease
Section titled “Diagnostic and Classification Systems for Atherosclerotic Disease”The classification of cerebral atherosclerosis often involves assessing the degree of arterial lumen narrowing, notablycarotid artery stenosis. This condition is diagnosed by specific criteria, including a threshold of 16% or more carotid artery stenosis, detected unilaterally or bilaterally via carotid imaging. [3]Additionally, diagnostic classification can utilize standardized coding systems such as International Classification of Disease (ICD)-9 or ICD-10 codes (specifically I65 for occlusion and stenosis of the carotid artery) or Current Procedural Terminology (CPT) codes for related interventions like endarterectomy.[3]
Severity is also assessed through quantitative measures like the Agatston score, which, in a modified form, is applied to coronary artery calcification (CAC) and abdominal aortic calcification (AAC). [1] A calcified lesion is operationally defined as an area of at least three connected pixels with a CT attenuation exceeding 130 Hounsfield Units, with the score calculated by multiplying the lesion’s area by a weighted CT attenuation score. [1] These measurements provide dimensional assessments of atherosclerotic burden, complementing categorical diagnoses.
Measurement Methodologies and Associated Phenotypes
Section titled “Measurement Methodologies and Associated Phenotypes”The detection and quantification of atherosclerosis in major arterial territories rely on advanced imaging techniques and physiological measurements.Carotid ultrasonography, specifically high-resolution B-mode ultrasonography, is the primary method for assessing cIMT and carotid plaque. [9] For quantifying calcification, multidetector computed tomography (MDCT) scan protocols are employed to measure CAC and AAC. [1] These methods provide objective data for research and clinical evaluation.
Other important measures of vascular health include the Ankle Brachial Index (ABI), used to assess peripheral arterial disease through ankle-brachial systolic blood pressure measurements.[1] Furthermore, cerebral blood flow is quantified by determining the cross-sectional area and flow velocity of major cerebral vessels, with total cerebral blood flow calculated by summing flow rates for the basilar and carotid arteries. [4]These measurements, alongside genetic correlation studies with outcomes like stroke and coronary heart disease, contribute to a comprehensive understanding of atherosclerotic disease.[9]
Signs and Symptoms
Section titled “Signs and Symptoms”Subclinical Vascular Changes and Imaging Markers
Section titled “Subclinical Vascular Changes and Imaging Markers”Cerebral atherosclerosis, the hardening and narrowing of arteries supplying the brain, often manifests initially through subclinical indicators detectable before overt symptoms emerge. Key among these are carotid intima-media thickness (cIMT) and carotid plaque, which are established measures of subclinical atherosclerotic disease[8], [9], [10]. [1] cIMT is defined as the mean maximum thickness of the common carotid artery wall, typically measured at the far or near wall, often averaged from multiple sites on both left and right arteries. [9] Carotid plaque, reflecting larger irregular arterial wall deposits, is defined by atherosclerotic thickening of the carotid artery wall [8]. [9] These subclinical changes are significant as they are predictive of future clinical events. [8]
Measurement of these subclinical signs is primarily achieved through non-invasive imaging techniques. High-resolution B-mode ultrasonography is widely used to assess both cIMT and the presence of carotid plaque in population samples, offering reasonable precision [8]. [9]Beyond carotid assessments, other imaging markers provide insights into cerebral vascular health. White matter lesions, indicative of small vessel disease, can be segmented from FLAIR scans using T1 tissue maps.[4] Cerebral blood flow (CBF) is another critical measure, with the cross-sectional area and flow velocity of vessels like the basilar and carotid arteries being determined from imaging, and total CBF calculated by summing flow rates. [4] Additionally, brain volume, including supratentorial gray and white matter, can be segmented from T1 images, reflecting potential structural changes associated with vascular compromise. [4]
Neurological Events and Clinical Manifestations
Section titled “Neurological Events and Clinical Manifestations”While cerebral atherosclerosis often presents initially as subclinical changes, its progression leads to significant neurological events and overt clinical manifestations, with stroke being the most prominent outcome[7], [9]. [11]Stroke can present in various clinical phenotypes, including ischemic stroke, cardio-embolic stroke, and small vessel disease stroke.[9]A severe manifestation of carotid atherosclerosis, directly impacting cerebral blood flow, is carotid artery stenosis, which involves occlusion and narrowing of the carotid artery, categorized by ICD-10 codes such as I65.[3] These clinical events represent critical symptomatic presentations and are the culmination of atherosclerotic processes.
The diagnostic significance of identifying subclinical atherosclerosis lies in its strong correlation with these serious clinical outcomes. Subclinical atherosclerosis traits are genetically correlated with the risk of coronary heart disease (CHD) and stroke, including ischemic stroke.[9] Specifically, carotid plaque has been shown to more strongly reflect atherosclerotic clinical events than cIMT, indicating its higher diagnostic value and predictive power for vascular events [9]. [11]Genetic correlations further highlight the biological relevance of these findings, suggesting shared genetic effects at certain loci between atherosclerosis in carotid and coronary arteries and clinical outcomes.[9]
Phenotypic Variability and Prognostic Indicators
Section titled “Phenotypic Variability and Prognostic Indicators”The presentation and progression of cerebral atherosclerosis and its related subclinical markers exhibit notable variability across individuals and demographic groups. Studies on subclinical atherosclerosis measures like cIMT often evaluate sex-specific and age-adjusted phenotypes to account for inter-individual variation.[1]Age-related changes are a significant factor, as atherosclerosis is a progressive disease, and its manifestations can differ across the lifespan. Furthermore, there can be heterogeneity in measurement techniques and definitions of subclinical markers across different studies; for instance, carotid plaque definitions have varied, encompassing either the presence of any plaque or stenosis exceeding a certain percentage.[8]This phenotypic diversity underscores the complex nature of atherosclerosis.
These variable subclinical measures serve as crucial prognostic indicators for future cardiovascular and cerebrovascular events. Measures of subclinical atherosclerosis are well-established predictors of incident clinical events.[8]The genetic correlations between subclinical atherosclerosis traits and clinical outcomes like CHD and stroke provide further insights into their prognostic value.[9]For example, stronger genetic correlation estimates for CHD with carotid plaque compared to cIMT suggest that plaque burden may be a more potent prognostic marker for certain cardiovascular outcomes.[9]Specific genetic variants (SNPs) showing consistent associations with multiple subclinical atherosclerosis measures may also have broader prognostic implications, warranting further research.[1]
Causes of Cerebral Atherosclerosis
Section titled “Causes of Cerebral Atherosclerosis”Cerebral atherosclerosis, a condition characterized by the hardening and narrowing of arteries supplying the brain, arises from a complex interplay of genetic predispositions, environmental exposures, and physiological factors that accumulate over a lifetime. Understanding these contributing causes is crucial for prevention and treatment strategies.
Genetic Predisposition and Molecular Pathways
Section titled “Genetic Predisposition and Molecular Pathways”The susceptibility to cerebral atherosclerosis is significantly influenced by inherited genetic factors. Studies on carotid plaque, a key marker of atherosclerosis, indicate a substantial heritable component, with estimates suggesting that 17% to 78% of its variability can be attributed to genetic influences.[11]This reflects a polygenic risk, where numerous genetic variants, each contributing a small effect, collectively determine an individual’s predisposition to the disease.[9]Furthermore, strong genetic correlations between subclinical atherosclerosis traits and clinical outcomes like coronary heart disease and stroke highlight shared genetic underpinnings across various cardiovascular conditions.[9]
Specific gene loci and their molecular pathways have been implicated in the development and progression of atherosclerosis. Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in genes such asPIK3CG, LDLR, EDNRA, and LRIG1 that are associated with carotid plaque. [11] Other genes, like KIAA1462, are critical for endothelial cell junctions and pathological angiogenesis, contributing to atherosclerosis in major arteries.[9] The genetic regulation of genes such as CCDC71L and PRKAR2B through vascular-specific expression quantitative trait loci (eQTLs) at the PIK3CGlocus suggests that genetic variation can influence cAMP-dependent pathways and smooth muscle cell apoptosis, directly impacting vascular integrity.[9] Genes like CREB3L3, involved in triglyceride metabolism andApoA-1 expression, and ITPR3, which regulates intracellular calcium release, also contribute to plaque formation through distinct biological mechanisms. [11]
Environmental Exposures and Lifestyle Influences
Section titled “Environmental Exposures and Lifestyle Influences”Environmental factors are significant contributors to the development of atherosclerosis. Traffic-related air pollution, a pervasive environmental exposure, is recognized as a global contributor to cardiovascular disease mortality and morbidity, including coronary atherosclerosis.[12]Exposure to these pollutants can induce inflammatory responses and oxidative stress within the vascular system, thereby accelerating the formation and progression of atherosclerotic plaques. Research often quantifies this exposure by assessing an individual’s residential proximity to major roadways, linking it directly to cardiovascular outcomes.[12]
Beyond environmental pollutants, established lifestyle and physiological risk factors play a dominant role in the pathogenesis of atherosclerosis. High blood pressure, cumulative smoking exposure (pack-years), elevated low-density lipoprotein cholesterol, and diabetes are well-documented vascular risk factors that substantially increase the burden of carotid plaque.[11]While these traditional factors account for a portion of the disease variability, their complex interplay with genetic predispositions underscores the multifactorial nature of atherosclerosis. Adopting healthy lifestyle practices, including balanced nutrition and regular physical activity, can effectively mitigate the impact of these risk factors on overall vascular health.[11]
Gene-Environment Interactions and Developmental Factors
Section titled “Gene-Environment Interactions and Developmental Factors”The development of atherosclerosis is often a result of intricate interactions between an individual’s genetic makeup and their environment, rather than independent influences. Genome-wide interaction studies (GWIS) have elucidated specific scenarios where genetic variants modify an individual’s response to environmental triggers, thus altering disease risk.[12] A notable example is the interaction identified between genetic variants within the PIGR-FCAMRlocus and residential exposure to traffic-related air pollution, which collectively influences the risk of coronary atherosclerosis.[12]Such interactions are critical in explaining why some individuals are more susceptible to environmental insults than others, highlighting the personalized nature of disease risk.
Developmental and epigenetic factors further modulate an individual’s predisposition to atherosclerotic disease. Epigenetic mechanisms, such as specific histone modifications including H3K4me1, H3K4me3, and H3K9ac, can alter gene expression without changing the DNA sequence, potentially mediating the long-term effects of early life experiences or chronic environmental exposures.[7] Moreover, the heritability of traits related to cerebral blood flow, which is vital for maintaining brain vascular health, has been shown to vary across different age groups. [4]This suggests that age-related physiological changes can modify the expression of genetic influences, indicating a dynamic interplay between genetics, epigenetics, and the aging process in determining atherosclerotic risk throughout life.
Comorbidities and Age-Related Vascular Changes
Section titled “Comorbidities and Age-Related Vascular Changes”Cerebral atherosclerosis is frequently intertwined with other cardiovascular diseases, sharing common genetic and pathological pathways. Conditions such as coronary heart disease (CHD) and various forms of stroke, particularly ischemic stroke, exhibit significant genetic correlations with subclinical atherosclerosis markers like carotid plaque.[9] Genes such as EDNRA, for instance, have been linked to both carotid plaque and coronary artery disease, pointing to shared genetic risk factors and biological mechanisms that contribute to widespread vascular pathology.[8]The presence of these comorbid conditions often indicates a systemic predisposition to vascular dysfunction and can accelerate the progression of cerebral atherosclerosis.
Advancing age represents a primary, non-modifiable risk factor for cerebral atherosclerosis. The cumulative impact of genetic predispositions and chronic environmental exposures over an individual’s lifetime contributes to the progressive thickening and hardening of arterial walls.[4]Studies consistently adjust for age when analyzing heritability of cerebral blood flow parameters, acknowledging its profound influence on vascular health and disease progression.[4]The observed age-dependent shifts in the heritability of vascular traits suggest that the genetic landscape influencing atherosclerosis is not static but dynamically evolves throughout an individual’s lifespan, emphasizing the need for age-stratified analyses to fully comprehend its complex etiology.
Biological Background of Cerebral Atherosclerosis
Section titled “Biological Background of Cerebral Atherosclerosis”Cerebral atherosclerosis is a chronic inflammatory condition characterized by the buildup of plaques within the arteries supplying the brain, leading to reduced blood flow and potential neurological impairment. This process is a localized manifestation of a systemic disease, deeply intertwined with broader metabolic and inflammatory conditions throughout the body. Understanding the molecular, genetic, and pathophysiological underpinnings of this condition is crucial for deciphering its development and progression.
The Pathophysiological Basis of Atherogenesis and Inflammation
Section titled “The Pathophysiological Basis of Atherogenesis and Inflammation”Atherogenesis, the foundational process of atherosclerosis, involves the progressive hardening and narrowing of arterial walls, ultimately leading to mature atherothrombosis. This process is of significant biological interest due to its strong epidemiological links to other metabolic dysfunctions. Specifically, research highlights a connection between the concentrations of plasma C-reactive protein (CRP) and the early stages of both diabetogenesis and atherogenesis, suggesting a shared or interconnected pathogenic pathway.[13]These findings indicate that systemic inflammatory markers, such as CRP, are not merely indicators but potentially active participants in the early development of vascular pathology. The progression from early atherogenesis to mature atherothrombosis involves a cascade of events that disrupt normal vascular homeostasis, ultimately impairing blood flow and affecting organ function, including that of the brain in cerebral atherosclerosis.[13]
Genetic Contributions to Metabolic Pathways and Inflammation
Section titled “Genetic Contributions to Metabolic Pathways and Inflammation”Genetic mechanisms play a crucial role in modulating an individual’s susceptibility to metabolic disturbances and inflammatory responses, which are central to atherogenesis. Studies have identified specific genetic loci related to metabolic-syndrome pathways, including LEPR, HNF1A, IL6R, and GCKR, that are significantly associated with plasma C-reactive protein levels. These associations suggest that inherited variations within these genes can influence systemic inflammation and metabolic health.[13] The genes LEPR, HNF1A, IL6R, and GCKR are integral to various metabolic functions. For example, LEPRis involved in leptin signaling related to energy balance,HNF1Ais a transcription factor critical for glucose metabolism,IL6R mediates inflammatory responses, and GCKRis implicated in glucose and lipid homeostasis. Alterations in these pathways, potentially influenced by genetic variants (SNPs), can lead to dysregulated metabolic processes and heightened inflammation, both of which are risk factors for the development of atherogenesis and its progression to mature atherothrombosis.[13]
C-Reactive Protein as a Key Biomarker and Mediator
Section titled “C-Reactive Protein as a Key Biomarker and Mediator”Plasma C-reactive protein (CRP) stands out as a critical biomolecule in the context of atherogenesis and related metabolic conditions. Elevated CRP concentrations are epidemiologically linked to the early stages of diabetogenesis and atherogenesis, suggesting its role as a significant indicator and possibly a mediator in these pathological processes. This acute-phase protein reflects systemic inflammation, and its association with metabolic-syndrome pathways further highlights the intricate connections between inflammation and metabolic health.[13]The impact of CRP levels on the progression of vascular disease, including mature atherothrombosis, is a subject of considerable interest. Genetic studies have reinforced the significance of CRP by demonstrating associations between SNPs in genes likeLEPR, HNF1A, IL6R, and GCKR and plasma CRP levels. These findings imply a complex regulatory network where genetic predispositions influence metabolic pathways, ultimately affecting systemic inflammatory markers like CRP, which in turn contribute to the risk of atherogenesis. [13]
Systemic Interconnections and Cerebral Vascular Health
Section titled “Systemic Interconnections and Cerebral Vascular Health”Cerebral atherosclerosis, as a specific manifestation of atherothrombosis, is profoundly influenced by systemic biological processes. The strong epidemiological links between plasma C-reactive protein concentrations, early diabetogenesis, and general atherogenesis underscore that cerebral vascular health is not isolated but is a component of overall systemic metabolic and inflammatory status. Disruptions in these broader homeostatic mechanisms contribute to the environment conducive for plaque formation in arteries throughout the body, including those supplying the brain.[13] The involvement of metabolic-syndrome pathways, mediated by genes such as LEPR, HNF1A, IL6R, and GCKR, in regulating plasma CRP levels illustrates a fundamental systemic connection. These pathways, when dysregulated, can predispose individuals to systemic inflammation and metabolic imbalances, which are direct drivers of atherogenesis. Consequently, understanding these systemic interconnections is vital for comprehending the development and progression of cerebral atherosclerosis and its impact on brain function.[13]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Genetic Predisposition and Core Metabolic Pathways
Section titled “Genetic Predisposition and Core Metabolic Pathways”Cerebral atherosclerosis is fundamentally influenced by metabolic pathways governing lipid homeostasis, with the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) serving as a critical control point in cholesterol biosynthesis. HMGCRcatalyzes the rate-limiting step in the mevalonate pathway, making its activity pivotal for cellular and systemic cholesterol levels. Common single nucleotide polymorphisms (SNPs) within theHMGCRgene are consistently associated with individual variations in low-density lipoprotein cholesterol (LDL-cholesterol) levels.[14]These genetic predispositions establish a foundational regulatory mechanism, influencing the baseline metabolic capacity for cholesterol synthesis and thus contributing to an individual’s susceptibility to atherosclerotic disease.
Post-Transcriptional Regulation via Alternative Splicing
Section titled “Post-Transcriptional Regulation via Alternative Splicing”Beyond direct genetic sequence variations, the precise regulation of HMGCR activity involves sophisticated post-transcriptional mechanisms, notably alternative splicing. Specific common SNPs in the HMGCR gene have been shown to affect the alternative splicing of exon 13. [14] This molecular process dictates which segments of the pre-mRNA are included in the final mature messenger RNA, leading to the production of different protein isoforms. Consequently, alterations in the splicing pattern of HMGCR exon 13 can result in a modified HMGCR protein, potentially impacting its enzymatic efficiency, stability, or responsiveness to other regulatory signals.
Impact on Lipid Metabolism and Flux Control
Section titled “Impact on Lipid Metabolism and Flux Control”The modified HMGCR protein isoforms, arising from SNP-influenced alternative splicing, directly perturb the metabolic pathway of cholesterol synthesis, altering its flux control. Changes in HMGCR function can lead to dysregulation in the rate at which cholesterol is produced within cells, thereby influencing the overall pool of circulating lipids. The association between these specific HMGCR SNPs and altered LDL-cholesterol levels underscores how fine-tuned genetic and post-transcriptional controls manifest as significant shifts in metabolic outputs. [14] This pathway dysregulation in cholesterol metabolism is a central mechanism contributing to the lipid imbalances characteristic of atherosclerotic progression.
Systems-Level Integration in Atherosclerotic Risk
Section titled “Systems-Level Integration in Atherosclerotic Risk”The molecular mechanisms governing HMGCRactivity and subsequent LDL-cholesterol levels are not isolated but are integrated into a broader biological system influencing cerebral atherosclerosis risk. Hierarchical regulation, from genetic variations impacting mRNA processing to the resulting altered enzyme activity, ultimately culminates in emergent properties at the systemic level, such as elevated circulating LDL-cholesterol. This systemic lipid dysregulation then interacts with other cellular and physiological networks, contributing to endothelial dysfunction, plaque formation, and the overall pathogenesis of atherosclerosis. Understanding these integrated pathways, where specific genetic polymorphisms influence post-transcriptional events to modulate metabolic flux, offers crucial insights into therapeutic targets for managing atherosclerotic disease.
Clinical Relevance
Section titled “Clinical Relevance”Diagnostic and Prognostic Value
Section titled “Diagnostic and Prognostic Value”Measures of carotid intima-media thickness (cIMT) and carotid plaque serve as crucial surrogate markers for subclinical atherosclerosis, providing significant diagnostic utility in assessing an individual’s cardiovascular risk. Carotid plaque, in particular, is noted to more strongly reflect atherosclerotic clinical events compared to cIMT, making it a powerful indicator for future vascular occurrences. High-resolution B-mode ultrasonography is commonly employed for the measurement of cIMT and the detection of carotid plaques, although variations in ultrasound protocols and plaque definitions across studies exist.[9]
The prognostic value of these markers is substantial, as increased cIMT and the presence of carotid plaques are established risk factors for severe outcomes such as myocardial infarction and stroke, especially in older adults. Genetic studies further support these observations by demonstrating overall genetic correlations between subclinical atherosclerosis traits and clinical outcomes like coronary heart disease (CHD) and various stroke subtypes. These insights are vital for identifying high-risk individuals and guiding early intervention strategies to mitigate long-term implications of disease progression.[1]
Genetic Insights and Personalized Prevention
Section titled “Genetic Insights and Personalized Prevention”Genome-wide association studies (GWAS) and colocalization analyses have significantly advanced the understanding of cerebral atherosclerosis by identifying specific genetic loci and genes associated with subclinical atherosclerosis traits. These studies have shown genetic correlations between carotid intima-media thickness, carotid plaque, and clinical outcomes such as CHD and stroke, with correlations for CHD often stronger with carotid plaque than with cIMT. Such genetic insights into the relationships between subclinical atherosclerosis, clinical outcomes, and tissue-specific gene regulation are crucial for uncovering the underlying biology.[9]
Understanding these genetic associations, including the heritability of cerebral blood flow, enables improved risk stratification and the development of personalized prevention strategies. Identifying genes such as KIAA1462, CCDC71L, PRKAR2B, ADAMTS9, CREB3L3, COL4A1, NFKB1, MSRA, and ZC3HC1offers potential targets for novel therapeutic interventions aimed at preventing or treating cerebral atherosclerosis. These findings suggest that vascular bed regulation may differ at distinct genomic regions, providing opportunities to identify specific targets for CHD or stroke prevention and treatment.[4]
Comorbidities and Therapeutic Targets
Section titled “Comorbidities and Therapeutic Targets”Cerebral atherosclerosis is intricately linked with various comorbidities, significantly impacting patient health and complicating disease management. For instance, cardiovascular disease, often driven by accelerated atherosclerosis, is a leading cause of morbidity and mortality in patients with rheumatoid arthritis, highlighting the systemic nature of the atherosclerotic process. Moreover, carotid artery stenosis, characterized by occlusion and narrowing, is a direct manifestation of advanced cerebral atherosclerosis.[10]
The presence of cerebral atherosclerosis is also associated with brain microbleeds (BMBs), which are themselves related to other manifestations of cerebral small vessel disease like white matter hyperintensities, lacunar stroke, and intracerebral hemorrhage, and predict outcomes such as any stroke, ischemic stroke, and Alzheimer’s disease. Insights into the molecular composition of atherosclerotic plaques, such as the role of collagen in the fibrous cap, or genetic pathways involvingCREB3L3in triglyceride metabolism andApoA-1expression, can inform the selection of targeted therapeutic approaches and monitoring strategies. These connections underscore the importance of a holistic approach to patient care, considering the broad implications of cerebral atherosclerosis.[15]
Key Variants
Section titled “Key Variants”Frequently Asked Questions About Cerebral Atherosclerosis
Section titled “Frequently Asked Questions About Cerebral Atherosclerosis”These questions address the most important and specific aspects of cerebral atherosclerosis based on current genetic research.
1. My dad had a stroke; does that mean I’m more likely to get one too?
Section titled “1. My dad had a stroke; does that mean I’m more likely to get one too?”Yes, your family history can definitely increase your risk. Genetic factors significantly influence how susceptible you are to atherosclerosis, including the hardening of arteries supplying the brain. Studies show that genes play a role in your likelihood of developing plaque buildup, which can lead to conditions like stroke. Knowing your family history is an important part of understanding your personal risk.
2. If I eat healthy and exercise, can I still get this if it runs in my family?
Section titled “2. If I eat healthy and exercise, can I still get this if it runs in my family?”It’s possible, but a healthy lifestyle can significantly reduce your risk. While genetic factors play a strong role in your susceptibility, how your genes interact with your environment – including your diet and exercise habits – is crucial. Personalized prevention strategies, often informed by genetic insights, aim to help you mitigate inherited risks through proactive lifestyle choices. So, while genetics might predispose you, lifestyle is a powerful tool.
3. Does my ethnic background change my risk for blocked brain arteries?
Section titled “3. Does my ethnic background change my risk for blocked brain arteries?”Yes, your ethnic background can influence your risk. Research has shown that genetic risk factors can differ across various ancestral groups. Many large genetic studies have historically focused on populations of European descent, meaning some genetic signals might be missed or have different effects in other populations. This is why multi-ancestry studies are so important for understanding risks across diverse communities.
4. How would I even know if my brain arteries are starting to narrow?
Section titled “4. How would I even know if my brain arteries are starting to narrow?”You often wouldn’t notice early signs yourself, as it’s typically “subclinical.” Doctors can assess your risk by looking for indicators like carotid intima-media thickness (cIMT) or plaque in your carotid arteries, which supply blood to your brain. These are signs of arterial health and overall atherosclerotic burden, and genetic studies help identify people at higher risk for these subclinical traits. Regular check-ups are key for early detection.
5. Why do some people get this, but others don’t, with similar habits?
Section titled “5. Why do some people get this, but others don’t, with similar habits?”A major reason is individual genetic differences. While lifestyle habits are important, genetic factors significantly influence a person’s susceptibility to developing atherosclerosis. Your unique genetic makeup can affect how your body handles inflammation, processes lipids, and maintains endothelial function, leading to varying levels of plaque buildup even among people with similar daily routines.
6. Can problems with my brain arteries affect my memory later on?
Section titled “6. Can problems with my brain arteries affect my memory later on?”Yes, absolutely. Beyond causing acute events like strokes, chronic narrowing of your brain arteries can lead to reduced blood supply to brain tissue over time. This ongoing lack of adequate blood flow can contribute to vascular cognitive impairment and even dementia, affecting your memory, thinking, and overall brain function as you age.
7. Is there a special test to tell me my genetic risk for this?
Section titled “7. Is there a special test to tell me my genetic risk for this?”While there isn’t one simple “yes/no” genetic test for immediate diagnosis, research is identifying specific genetic markers. Genome-wide association studies (GWAS) have pinpointed numerous genetic locations linked to traits like carotid plaque and artery narrowing, which indicate atherosclerosis risk. This genetic information helps improve how doctors stratify your risk and could lead to more personalized prevention plans in the future.
8. Why do I seem to get high cholesterol even when I eat well?
Section titled “8. Why do I seem to get high cholesterol even when I eat well?”Genetics can play a significant role in how your body processes cholesterol, even with a healthy diet. Your genes influence various biological pathways involved in lipid accumulation, which contributes to plaque formation. So, while diet is crucial, some people are genetically predisposed to higher cholesterol levels or a greater tendency for plaque buildup regardless of their careful eating habits.
9. What can I do now if I’m worried about my brain arteries?
Section titled “9. What can I do now if I’m worried about my brain arteries?”The best approach is to focus on preventive strategies and early risk assessment. Talk to your doctor about your family history and any lifestyle concerns. They might recommend screenings for subclinical atherosclerosis, like checking your carotid arteries, to identify early signs. Understanding your genetic susceptibility can also help guide personalized prevention plans to keep your arteries healthy.
10. Does this problem just naturally get worse as I get older?
Section titled “10. Does this problem just naturally get worse as I get older?”Atherosclerosis is a progressive condition, meaning plaques tend to grow and stiffen over time if not managed. This natural progression can lead to more significant obstruction of blood flow and increased risk of complications. While age is a factor, understanding your genetic predispositions and adopting preventive measures can influence the rate at which the disease progresses.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] O’Donnell, C. J. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S4.
[2] Franceschini, N., et al. “GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes.”Nat Commun, vol. 8, no. 1, 2017, p. 15734.
[3] Palmer, M. R. “Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network.” Genetic Epidemiology, vol. 45, no. 1, 2021, pp. 4-15.
[4] Ikram, M. A. “Heritability and genome-wide associations studies of cerebral blood flow in the general population.” Journal of Cerebral Blood Flow & Metabolism, vol. 37, no. 11, 2017, pp. 3616-3625.
[5] ENCODE Project Consortium. “An integrated encyclopedia of DNA elements in the human genome.” Nature, vol. 489, no. 7414, 2012, pp. 57–74.
[6] Goldstein, L. B., et al. “Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Interdisciplinary Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the American Academy of Neurology.”Stroke, vol. 37, no. 6, 2006, pp. 1583–1633.
[7] Malik, R et al. “Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.”Nature Genetics, vol. 50, no. 4, Apr. 2018, pp. 524-533. PMID: 29531354.
[8] Bis, J. C., et al. “Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque.” Nat Genet, vol. 43, no. 10, 2011, pp. 940-947.
[9] Franceschini, N et al. “GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes.”Nature Communications, vol. 9, no. 1, 3 Dec. 2018, p. 5070. PMID: 30510157.
[10] Lopez-Mejias, R., et al. “A genome-wide association study identifies a 3’UTR genetic variant of RARBassociated with carotid intima-media thickness in rheumatoid arthritis.”Arthritis Rheumatol, vol. 71, no. 3, 2019, pp. 385-393.
[11] Dueker, N. D., et al. “Extreme Phenotype Approach Suggests Taste Transduction Pathway for Carotid Plaque in a Multi-Ethnic Cohort.” Stroke, vol. 51, no. 10, 2020, pp. 2884–2892.
[12] Ward-Caviness, C. K., et al. “A genome-wide trans-ethnic interaction study links the PIGR-FCAMRlocus to coronary atherosclerosis via interactions between genetic variants and residential exposure to traffic.”PLoS One, vol. 12, no. 3, 2017, pp. e0173621.
[13] Ridker, P. M. “Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women’s Genome Health Study.”American Journal of Human Genetics, vol. 82, no. 5, May 2008, pp. 1190-1197.
[14] Burkhardt, R. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2009.
[15] Knol, M. J., et al. “Association of common genetic variants with brain microbleeds: A Genome-wide Association Study.” Neurology, vol. 95, no. 24, 2020, pp. e3305-e3316.